Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Low-dose Glucocorticoid Vasculitis Induction Study
- Status
- UNKNOWN
- Phase
- PHASE4
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
- Status
- COMPLETED
- Phase
- PHASE2
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
- Status
- COMPLETED
- Phase
- PHASE4
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
- Status
- WITHDRAWN
- Phase
- PHASE3
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
- Status
- COMPLETED
- Phase
- PHASE4
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
- Status
- COMPLETED
- Phase
- PHASE2
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2